• 동의신경정신과학회지
• /
• 제26권4호
• /
• pp.349-356
• /
• 2015

Objectives: Schizophrenia is difficult to treat effectively and the antipsychotics used have many side effects. However, few studies have focused on the combined treatment of Korean and Western medicine as an alternative. In this study, we reported an inpatient with chronic schizophrenia who was treated by a combination of Korean and Western medicine. Methods: We experienced a case of a diagnosed schizophrenia patient as whose chief complaint was avolition, diminished emotional expression and hallucination. The patient was treated with Western medicine and Korean traditional treatment including acupuncture, moxa and herbal medicine. The Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) were used for assessment. Results: After treatment, symptoms involving avolition, diminished emotional expression and hallucination were improved; furthermore, the scores of the BPRS and the PANSS were decreased by approximately 50%, respectively. In addition, there were no notable side effects. Conclusions: The combined treatment of Korean and Western medicine can be an effective and well-tolerated treatment modality for patients with chronic schizophrenia.

• 정신신체의학
• /
• 제13권1호
• /
• pp.32-40
• /
• 2005

연구목적 : 이 연구는 정신분열병 입원환자를 대상으로 감정표현 불능증과 임상변인 및 정신분열병의 연관 관계를 조사하고자 시행되었다. 방법: 두 대학병원 정신과 입원 시설에서 1년간 연속적인 수집을 통해 58명의 성인 정신분열병 환자가 이 연구에 참여하였다. 환자들에게 감정표현 불능증 척도(Toronto Alexithymia Scale, TAS), 양성 및 음성 증상척도(Positive and Negative Symptom Scale, PANSS), 간이정신진단검사(Symptom Checklist-90-Revised, SCL-90-R)를 시행하였다. 결과: 그 결과 TAS 총점은 SCL-90-R의 모든 하위 척도와 정적 상관 관계를 보였으며, 기존의 연구 결과와는 달리 PANSS의 양성증상, 음성증상, 일반 정신병리 척도 점수와는 유의한 상관이 없었다. 또한 '주관적 감각과 감정 경험의 혼동' 요인과 '감정 표현의 곤란' 요인은 SCL의 증상 척도와 유의하게 정적 상관하였으나, '공상의 빈곤'은 일부 하위척도와 부정 상관, '외부 지향적 사고'는 상관관계가 없었다. 다중회귀분석 결과는 SCL-90-R의 전체심도지수(GSI)가 감정표현 불능증의 28.2%를 설명하는 것으로 나타났다. 결론: 이 결과 및 객관적, 주관적 검사의 소견의 차이는 정신분열병의 감정표현 불능증이 두 가지 구성체, 즉 '감정 표현과 소통의 장애(상태적 요인)'과 '외부 지향적 사고(특성적 요인)'로 구성됨을 시사한다. 향후 정신분열병 환자를 대상으로 한 TAS의 구성 타당도 연구가 필요하다.

• 대한핵의학회지
• /
• 제31권3호
• /
• pp.310-319
• /
• 1997

본 연구는 정신분열병 환자의 치료후의 국소뇌혈류량의 변화 및 증상호전과의 관계를 알아보기 위하여 시행되었다. DSM-IV 진단기준에 의거한 총 11명의 정신분열병 환자를 대상으로 치료전과 치료 6주째에 $^{99m}Tc$-HMPAO 뇌 SPECT를 실시하였으며 동시에 PANSS를 사용하여 정신병리를 함께 평가하였다. 대상자들은 입원전 최소 2주간의 항정신병 약물 비복용기간을 거친 환자들이었으며 이중 3명은 과거 항정신병약물의 복용력이 없는 사람들이었다. 6주간의 약물 치료훼 환자들은 증상의 호전 정도에 따라 호전군과 비호전군으로 나누어졌으며 이들간의 뇌국소혈류지수를 비교하였다. 결과적으로 전두엽의 혈류지수는 양집단 모두에서 감소하였고 집단간의 차이는 없었다. 그러나 조측 측두엽의 혈류량은 호전군에서 유의하게 많이 감소하였고 또한 우측 측두엽의 혈류량의 감소량은 PANSS 총점의 감소량과 상관관계를 나타내었다. 이러한 결과는 정신분열병의 증상과 측두엽의 활동성간의 관계를 시사하는 소견이라고 하겠다.

• 생물정신의학
• /
• 제14권3호
• /
• pp.177-183
• /
• 2007

목 적: 성상세포(astrocyte)에서 생산되어 신경세포의 증식과분화에 관여하는 S100B 단백이 정신분열병의 진행과 증상론과 관련이 있다는 연구가 계속 진행되고 있다. 이에 정신분열병 환자와 정상대조군의 혈청 S100B 농도를 비교하고, 정신분열병 환자의 증상 양상과 S100B 농도와의 연관성을 연구하였다. 방 법: DSM-IV-TR 진단 기준에 따라 정신분열병으로 진단받은 환자 중 정신분열병 최초 발병 환자 혹은 최소 6개월 간 약물 치료를 하지 않은 정신분열병 환자 21명과 정상대조군 27명의 혈청 S100B 농도를 비교하였으며, 정신분열병 환자의 PANSS 전체점수와 양성증상점수, 음성 증상점수 등과 S100B의 혈청농도 간의 상관관계에 대해서 알아보았다. 결 과: 정신분열병 환자에서의 S100B 혈청농도($0.074{\pm}0.039$ ng/ml)와 정상대조군에서의 S100B 혈청 농도($0.072{\pm}0.030$ng/ml)에는 통계적인 차이는 없었다(p=0.925). 또한, 음성증상점수와 S100B 혈청농도(${\rho}$=0.410, p=0.065 ; 표 3)의 상관관계 및 양성증상점수와 S100B 혈청농도 (${\rho}$=-0.390, p=0.080 ; 표 3)의 상관관계는 통계적으로 유의하지 않았다. 결 론: 이번 연구에서 S100B 혈청농도와 정신분열병과의 관련성을 뚜렷하게 발견하기 어려웠다. 이러한 S100B의 역할과 연관성을 확인하기 위해서 연구대상의 확대와 CSF에서의 농도 측정, 장기적 추적 검사, 다른 관련 물질과의 연관성에 대한 추가적인 연구가 필요하다.

• 생물정신의학
• /
• 제24권4호
• /
• pp.188-195
• /
• 2017

Objectives Schizophrenia is characterized by disturbances in perception and cognition. Attenuated mismatch negativity (MMN) reflects central auditory dysfunction in schizophrenia. The aim of this study is to compare MMN changes before and after treatment in schizophrenia patients and to assess their association with treatment response. Methods Twenty-three schizophrenia patients underwent an oddball paradigm. MMN was calculated by the difference waveforms of the event-related potentials (ERPs) elicited by subtracting standard from deviant stimulus. The clinical symptoms were measured by the Positive and Negative Syndrome Scale (PANSS), the Psychotic Symptom Rating Scale (PSYRATS). Follow-up evaluation was conducted when the PANSS total score decreased by 30% or more (treatment response group) or before discharge (non-response group). Results The treatment response group showed significantly larger MMN amplitude improvement and latency reduction than the non-response group after treatment (Fz ; mean amplitude p = 0.035, FCz ; p = 0.041). The auditory hallucination group showed shorter latency than that of the group without hallucinations. Additionally, auditory hallucination was associated with prolonged MMN latency and shortened after treatment in the auditory hallucination response group (Fz ; p = 0.048). Conclusions These results suggest that the attenuated MMN amplitude reflects the progression of the disease. The increment of MMN amplitude and shortening of latency after treatment may reflect cognitive functional recovery of central auditory sensory processing.

• 생물정신의학
• /
• 제13권3호
• /
• pp.191-201
• /
• 2006

Objectives : The purpose of this study was to investigate whether the cognitive functions would be correlated with psychotic symptoms and whether antipsychotic treatments would affect the cognitive functions after 8 weeks. Methods : The thirty-five schizophrenic patients were conducted in this study. The psychopathology was measured using PANSS. The memory function, executive function, and sustained attention were measured using Memory Assessment Scale(MAS), Wisconsin Card Sorting Test(WCST), and Vigilance(VIG) and Cognitrone(COG) in Vienna Test System. After 8 weeks of antipsychotic treatment, we retested the cognitive tests. Results : 1) The cognitive tests after the 8 week's treatment showed significant improvements in memory and executive function in the schizophrenic patients. On the other side, sustained attention did not show improvement. 2) The change of PANSS were correlated with perseverative response, perseverative error and total correct in WCST at baseline. WCST scores at baseline were correlated with negative symptoms, but not positive ones. Conclusion : These study suggests that 1) the impaired sustained attention could be a vulnerability marker in schizophrenia, 2) memory & executive function deficit could be reversible after treatment, and 3) medication might have a benefit in improving the cognitive functions in schizophrenia. Furthermore, the data supports that the better premorbid executive function was, the more favorable was the treatment response in schizophrenic patients. Finally, this study indicates that executive function might be an index of treatment improvement.

• 생물정신의학
• /
• 제3권2호
• /
• pp.262-268
• /
• 1996

It has been known that clozapine is more selective mesolimbic dopamin $D_2$ receptor antagonist and related to 5-HT receptor. In this study, we wxamined the plasma homovanillic acid(HVA), serotonin(5-HT), and 5-hydroxyindoleacetic acid(5-HIM) levels in refractory schizophrenics during clozapine treatment. And we assessed the effects of clozapine on these plasma monoamine metabolites and their association with psychopathology and treatment response. Eight refractory schizophrenic patients(DSM-IV) have entered the study for 3 months during clozapine treatment. Patients were admitted to the inpatient sevice and withdrawn from all neuroleptics for 7-14 days but exceptionally occasional doses of lorazepam was given if needed for behavioral control. The dose of clozapine was titrated as tolerated to 800mg/day. The plasma HVA. 5-HIM and 5-HT levels were measured before treatment and following 2nd week, 4th week, 8th week, and 12th during treatment. Psychopathology was assessed with Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Synrome Scale(PANSS) before and during clozapine treatment. During clozapine treatment, no statistically significant changes were found in plasma HVA, 5-HIM, 5-HT levels, and HVA/5-HIM ratio between baseline and following 2nd week, 4th week, 8th week, 12th week. However, the change in plasma 5-HIAA/5-HT ratio from baseline to 4th week was statistically significant. Generally, changes of plasma HVA, 5-HIAA, 5-HT levels and HVA/5-HIAA ratio were not associated with psychopathology but 5-HIAA was associated with in positive symptoms and general psychopathology of PANSS. These results suggest that clozapine has been found to have relatively weak dopaminergic blokade and stronger serotonergic antagonism.

• 생물정신의학
• /
• 제3권2호
• /
• pp.251-257
• /
• 1996

Selective serotonin reuptake inhibitors(SSRIs), as haloperidol, ore metabolized in the cytochrome P450IID6. They can cause inhibition of metabolism of antipsychotics to elevate the serum level of antipsychotics and exacerbate the extrapyramidal symptoms when co-administered with antipsychotics. Among these SSRIs, there ore a few studies about paroxetine compared to fluoxetine or sertraline. In this study, we have intended to know the drug interaction of paroxetine and haloperidol when co-administered two drugs for the chronic schizophrenics by assessing the changes of positive, negative symptoms and extrapyramidal symptoms. for this purpose, we selected 29 subjects, the chronic schizophrenics with no physical problems. They were under maintenance therapy of haloperidol. They ore randomly assigned to placebo group(n=12) and drug group(n=17) by using double blind method. And then, placebo or paroxetine 20mg were administered to the subjects of each groups during 8 week period. We have assessed their psychopathology and extrapyramidal symptoms using Positive and Negative Syndrome Scale(PANSS), Hamilton Rating Scale lor Depression(HRSD), Simpson-Angus Scale at 0, 2, 4, 6, 8 weeks and serum haloperidol, reduced haloperidol levels at 0, 4, 8 weeks during the period. The results ore analysed by using repeated measure MANOVA. 27 subjects have completed the study during 8 weeks. among the subjects, 1) PANSS, HRSD ; no significant difference between groups. 2) Simpson-Angus Scale ; no significant change according to the time and no significant difference between the groups(no group and time effect). 3) Haloperidol and reduced haloperidol level ; no significant change. When co-administered paroxetine and haloperidol, there ore no significant changes of the psychopothology and no significant changes of the extrapyramidal symptoms. In this result, paroxetine seems to be not to affect the metabolism of haloperidol.

• 생물정신의학
• /
• 제18권4호
• /
• pp.225-231
• /
• 2011

Objectives Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is receiving growing attention. The aim of this study was to investigate the association between therapeutic response to atypical antipsychotics and weight gain in admission status. Methods The study was conducted for Korean inpatients with schizophrenia in a university hospital in Seoul, between Jan 2006 and Dec 2010. Data was collected by reviewing the medical record of 39 consecutively hospitalized patients with Schizophrenia (DSM-IV) at a university hospital. Positive and Negative Symptom Scale (PANSS), Body Mass Index (BMI) and body weights were measured. Results No significant difference was observed for sex, age, illness onset age, family history of schizophrenia, numbers of hospitalization before treatment, educational years, marriage status, occupational status and subtype of schizophrenia between weight gainers and non-weight gainers. Regarding treatment response to atypical antipsychotics, weight gainers show significantly more PANSS decrease than non-weight gainers during admission period. Conclusions Our findings suggest that it appears to be more likely to respond to atypical antipsychotics in weight gainers than non-weight gainers (that weght gainers appear to be more likely to respond to atypical antipsychotics than non-weight gainers). These results show that the antipsychotic-induced body weight gain is associated with therapeutic response of antipsychotics in Korean inpatients with schizophrenia.

• 생물정신의학
• /
• 제25권2호
• /
• pp.38-43
• /
• 2018

Objectives Dopamine dysregulation has been regarded as one of the core pathologies in patients with schizophrenia. Since dopamine synthesis capacity has found to be inconsistent in patients with schizophrenia, current classification of patients based on clinical symptoms cannot reflect the neurochemical heterogeneity of the disease. Here we performed new subtyping of patients with first-episode psychosis (FEP) through biotype-based cluster analysis. We specifically suggested basal ganglia structural changes as a biotype, which deeply involves in the dopaminergic circuit. Methods Forty FEP and 40 demographically matched healthy participants underwent 3T T1 MRI. Whole brain parcellation was conducted, and volumes of total 6 regions of basal ganglia have been extracted as features for cluster analysis. We used K-means clustering, and external validation was conducted with Positive and Negative Syndrome Scale (PANSS). Results K-means clustering divided 40 FEP subjects into 2 clusters. Cluster 1 (n = 25) showed substantial volume decrease in 4 regions of basal ganglia compared to Cluster 2 (n = 15). Cluster 1 showed higher positive scales of PANSS compared with Cluster 2 (F = 2.333, p = 0.025). Compared to healthy controls, Cluster 1 showed smaller volumes in 4 regions, whereas Cluster 2 showed larger volumes in 3 regions. Conclusions Two subgroups have been found by cluster analysis, which showed a distinct difference in volume patterns of basal ganglia structures and positive symptom severity. The result possibly reflects the neurobiological heterogeneity of schizophrenia. Thus, the current study supports the importance of paradigm shift toward biotype-based diagnosis, instead of phenotype, for future precision psychiatry.